Testosterone for Women: Waiting for the Female Aphrodisiac by John Hoberman, PhD

[Millard Baker]

Testosterone for Women: Waiting for the Female Aphrodisiac by John Hoberman, PhD

In December 2004 a U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs refused to recommend Procter & Gamble's Intrinsa testosterone patch for female sexual dysfunction. The FDA panel found that administering testosterone to these patients would produce an average of one extra sexual encounter a month, a benefit that in the panel's view did not justify exposing women to the risk of heart attacks and strokes. This decision surprised executives at both Procter & Gamble and at BioSante Pharmaceuticals, Inc., its principal rival in the race to develop a mass-marketed male hormone sex stimulant for women. BioSante had been rooting for P& G's application because it believed its own testosterone delivery systems – gels, creams, nasal sprays, and pills – would outperform the Intrinsa transdermal testosterone patch both as drug delivery vehicles and thus in the marketplace.


http://www.mesomorphosis.com/articles/hoberman/testosterone-for-women.htm